Related Experiment Video
Updated: Jul 13, 2025
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
16.6K
Long acting growth hormone (LAGH), an update
Margaret Steiner Grillo1, Jacklyn Frank1, Paul Saenger1
1Pediatric Endocrinology, NYU Langone Hospital-Long Island, Mineola, NY, United States.
Frontiers in Pediatrics
|October 16, 2023
Summary
New long-acting growth hormone (GH) formulations offer improved patient adherence by reducing daily injection frequency. These advanced therapies demonstrate comparable safety and efficacy to daily somatropin, addressing a long-standing need in pediatric endocrinology.
Area of Science:
- Endocrinology
- Pharmacology
- Biotechnology
Background:
- Growth hormone (GH) deficiency historically treated with pituitary-derived GH.
- Recombinant GH (somatropin) introduced in 1985, requiring daily subcutaneous injections.
- Pediatric endocrine community sought long-acting GH formulations to improve patient adherence.
Purpose of the Study:
- To review the development and efficacy of long-acting recombinant GH formulations.
- To assess the safety and tolerability profiles of these novel therapies.
- To evaluate the impact on patient adherence compared to daily injections.
Main Methods:
- Review of four distinct long-acting GH formulation types: pegylated, prodrug, albumin-binding, and fusion proteins.
- Analysis of Phase 3 clinical study data for non-inferiority and safety.
- Assessment of adherence profiles in clinical trials.
Main Results:
- Four long-acting GH formulations are available or nearing approval.
- All formulations demonstrated non-inferiority to daily somatropin in Phase 3 studies.
- Safety and tolerability profiles are comparable to daily somatropin, with excellent adherence.
Conclusions:
- Long-acting recombinant GH formulations represent a significant advancement in treating GH deficiency.
- These therapies offer a convenient alternative to daily injections, improving patient adherence.
- The developed formulations maintain safety and efficacy, meeting a critical clinical need.
More Related Videos
03:22Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
15.1K
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
18.1K
Related Concept Videos
01:24Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
01:16Insulin: Dosing Regimen and Adverse Effects
185
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
185
01:27Insulin Formulations: Types and Delivery
205
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
205
01:15Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
01:17Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
01:16Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K